These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6408234)

  • 21. Valproate-associated carnitine deficiency and malignant cerebral edema in the absence of hepatic failure.
    Triggs WJ; Gilmore RL; Millington DS; Cibula J; Bunch TS; Harman E
    Int J Clin Pharmacol Ther; 1997 Sep; 35(9):353-6. PubMed ID: 9314085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valproic acid impairs carnitine uptake in cultured human skin fibroblasts. An in vitro model for the pathogenesis of valproic acid-associated carnitine deficiency.
    Tein I; DiMauro S; Xie ZW; De Vivo DC
    Pediatr Res; 1993 Sep; 34(3):281-7. PubMed ID: 8134167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreased serum carnitine in valproate induced Reye syndrome.
    Böhles H; Richter K; Wagner-Thiessen E; Schäfer H
    Eur J Pediatr; 1982 Nov; 139(3):185-6. PubMed ID: 6819143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Secondary carnitine deficiency].
    Yorifuji S
    Ryoikibetsu Shokogun Shirizu; 2001; (36):51-3. PubMed ID: 11596448
    [No Abstract]   [Full Text] [Related]  

  • 25. [Valproic acid and stupor].
    Vanhooren GT
    Ned Tijdschr Geneeskd; 1991 Feb; 135(5):191-2. PubMed ID: 2002873
    [No Abstract]   [Full Text] [Related]  

  • 26. The role of carnitine supplementation in valproic acid therapy.
    Kelley RI
    Pediatrics; 1994 Jun; 93(6 Pt 1):891-2. PubMed ID: 8190571
    [No Abstract]   [Full Text] [Related]  

  • 27. [A severe disabled case of incomplete Fanconi syndrome after discontinuation of carnitine supplementation during valproate sodium therapy].
    Ono H
    No To Hattatsu; 2007 May; 39(3):226-7. PubMed ID: 17515139
    [No Abstract]   [Full Text] [Related]  

  • 28. [The problems of valproate therapy in severely handicapped children--valproate induced hyperammonemia and hypocarnitinemia].
    Matsui K; Iwamoto H; Ohtsuki N; Kobayashi T; Miyake S; Yamada M
    No To Hattatsu; 1991 Jan; 23(1):32-8. PubMed ID: 1825272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Carnitine deficiency with valproate sodium therapy--the difference by normal diet and enteral nutrition].
    Kato A
    No To Hattatsu; 2013 Jan; 45(1):17-20. PubMed ID: 23593740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The decreased level of plasma carnitine in patients with epilepsy].
    Belousova ED
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):106-110. PubMed ID: 28745680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
    Yamada H; Shishido T; Mukai T; Araki M; Naka H; Tokinobu H
    Rinsho Shinkeigaku; 2019 May; 59(5):258-263. PubMed ID: 31061301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A case report of valproate encephalopathy].
    Miyamoto T; Miyamoto M; Hirata K; Katayama S
    Rinsho Shinkeigaku; 1999 Oct; 39(10):1075-7. PubMed ID: 10655774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet.
    Coppola G; Epifanio G; Auricchio G; Federico RR; Resicato G; Pascotto A
    Brain Dev; 2006 Jul; 28(6):358-65. PubMed ID: 16376041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatotoxic effects in a child receiving valproate and carnitine.
    Murphy JV; Groover RV; Hodge C
    J Pediatr; 1993 Aug; 123(2):318-20. PubMed ID: 8345435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carnitine supplementation for valproate-related hyperammonemia to maintain therapeutic valproate level.
    Sonik P; Hilty DM; Rossaro L; Bourgeois JA
    J Clin Psychopharmacol; 2011 Oct; 31(5):680-2. PubMed ID: 21881462
    [No Abstract]   [Full Text] [Related]  

  • 36. Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy.
    Mock CM; Schwetschenau KH
    Am J Health Syst Pharm; 2012 Jan; 69(1):35-9. PubMed ID: 22180549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does carnitine administration improve the symptoms attributed to anticonvulsant medications?: a double-blinded, crossover study.
    Freeman JM; Vining EP; Cost S; Singhi P
    Pediatrics; 1994 Jun; 93(6 Pt 1):893-5. PubMed ID: 8190572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Valproate-associated hyperammonemia and DL-carnitine supplement.
    Komatsu M; Kodama S; Yokoyama S; Konishi H; Tanaka K; Momota K; Wada H; Matsuo T
    Kobe J Med Sci; 1987 Jun; 33(3):81-7. PubMed ID: 2959815
    [No Abstract]   [Full Text] [Related]  

  • 39. Intractable epilepsy.
    Shuper A; Gutman A; Mimouni M
    Lancet; 1999 Apr; 353(9160):1238. PubMed ID: 10217085
    [No Abstract]   [Full Text] [Related]  

  • 40. Exacerbation of mood symptoms associated to primary and secondary carnitine deficiency: a case report.
    Santos-Cubiñá J; Torres-Rodríguez A; Castaing-Lespier PA; Sabaté N; Torres-Martin A; Carlo S
    Bol Asoc Med P R; 2013; 105(3):43-4. PubMed ID: 24282920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.